Haldol Depot (Haloperidol Decanoate)

Haldol Depot is indicated for several psychiatric indications where long‑acting antipsychotic coverage is desired.

• Maintenance therapy for schizophrenia in patients who have responded to oral haloperidol.
• Acute exacerbations of schizophrenia when rapid stabilization is needed and oral administration is impractical.
• Treatment of acute psychotic episodes associated with bipolar disorder or schizoaffective disorder.
• Adjunctive therapy for patients with chronic psychosis who have adherence challenges.

Side effects of Haldol Depot reflect its dopamine‑blocking activity and can vary in frequency and severity.

Common

• Sedation or drowsiness.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.

Serious

• Neuroleptic malignant syndrome, a rare but life‑threatening reaction.
• Tardive dyskinesia, characterized by involuntary movements.
• Severe hypotension or cardiac arrhythmias.
• Elevated prolactin levels leading to galactorrhea or menstrual disturbances.

Before initiating Haldol Depot, clinicians should evaluate patient history and monitor for conditions that may increase risk.

• History of cardiovascular disease, including arrhythmias or recent myocardial infarction.
• Pre‑existing movement disorders such as Parkinson’s disease or Huntington’s disease.
• Severe hepatic or renal impairment that could affect drug clearance.
• Pregnancy, lactation, or plans to become pregnant, given limited safety data.
• Concomitant use of other central nervous system depressants.
• Elderly patients, especially those with dementia‑related psychosis, due to higher sensitivity to adverse effects.

Haldol Depot can interact with several medications, altering its efficacy or increasing the risk of adverse events.

Avoid

• Other dopamine antagonists or antipsychotics, which may potentiate extrapyramidal effects.
• Medications that prolong the QT interval, increasing risk of cardiac arrhythmias.
• Strong CYP3A4 inducers such as carbamazepine, which can reduce haloperidol levels.

Use with caution

• CNS depressants including benzodiazepines, opioids, or alcohol, which may enhance sedation.
• Anticholinergic agents used to treat extrapyramidal symptoms, as they may mask early signs.
• Drugs that affect prolactin levels, such as estrogen therapy, which could exacerbate hormonal side effects.